The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE

OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8

COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
ALKERMES PLC SHS G01767105 418,252 14,040,000 SH   SOLE   14,040,000 0 0
AMARIN CORP PLC SPONS ADR NEW 023111206 35,757 23,998,000 SH   SOLE   23,998,000 0 0
BIOCRYST PHARMACEUTICALS INC COM 09058V103 14,715 1,390,790 SH   SOLE   1,390,790 0 0
BIOGEN INC COM 09062X103 131,133 643,000 SH   SOLE   643,000 0 0
GILEAD SCIENCES INC COM 375558103 82,943 1,341,900 SH   SOLE   1,341,900 0 0
INNOVIVA INC COM 45781M101 97,623 6,614,000 SH   SOLE   6,614,000 0 0
IRONWOOD PHARMACEUTICALS INC COM CL A 46333X108 188,977 16,390,000 SH   SOLE   16,390,000 0 0
MERSANA THERAPEUTICS INC COM 59045L106 19,863 4,299,297 SH   SOLE   4,299,297 0 0
PEAR THERAPEUTICS INC CLASS A COM 704723105 771 500,356 SH   SOLE   500,356 0 0
REGULUS THERAPEUTICS INC COM 75915K309 383 185,183 SH   SOLE   185,183 0 0
VOR BIOPHARMA INC COM 929033108 3,071 618,000 SH   SOLE   618,000 0 0